பெறுகிறது மூலோபாய முதலீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பெறுகிறது மூலோபாய முதலீடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பெறுகிறது மூலோபாய முதலீடு Today - Breaking & Trending Today

GOAT Group Gets Strategic Investment - socaltech.com

socaltech.com
Los Angeles-based
GOAT, best known for its online marketplace for sneakers, but which now also has expanded into apparel and accessories, has received a strategic investment from
Groupe Artemis. Groupe Artemis is owner of the Kering luxury fashion brand. Size of the investment was not announced. GOAT said the strategic investment follows its Series E funding announcned in September of 2020, which was worth $100M, valuing GOAT at $1.75 billion. GOAT said the new investment round will go towards continued expansion in the fashion apparel and other new categories. GOAT is led by co-founder and CEo Eddy Lu. ....

Ceo Eddy Lu , Group Gets Strategic Investment , Gets Strategic Investment , Groupe Artemis , G Oat , சிஇஓ எடி லு , குழு பெறுகிறது மூலோபாய முதலீடு , பெறுகிறது மூலோபாய முதலீடு , குழு ஆர்ட்டெமிஸ் , க் ஓட்ஸ் ,

CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data

CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data
WASHINGTON (dpa-AFX) - Today s Daily Dose brings you news about BioCryst s update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, Supernus phase III study results of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder, and Spectrum s progress with Poziotinib for non-small cell lung cancer.
Read on.
1. BioCryst Not to Pursue COVID-19 indication for antiviral Galidesivir
Shares of BioCryst Pharmaceuticals Inc. (BCRX) dropped more than 8% on Tuesday after the company announced that it will no longer be pursuing the COVID-19 indication for its investigational broad-spectrum antiviral Galidesivir. ....

District Of Columbia , United States , Christopherj Schaber , Cyclacel Pharma , Cyclacel Pharmaceuticals Inc , Beam Therapeutics Inc , National Institute Of Allergy , National Institutes Of Health , Sigilon Therapeutics Inc , Venus Concept Inc , Supernus Pharmaceuticals Inc , Soligenix Inc , Spectrum Pharmaceuticals Inc , Biocryst Pharmaceuticals Inc , Spero Therapeutics Inc , Daily Dose , Acorn Bioventures , Cryst Not , Biocryst Pharmaceuticals , National Institute , Infectious Diseases , National Institutes , Gets Strategic Investment , Seriesb Preferred Stock , Gets The Much Needed , Clinical Global Impression ,